August 1, 2017 / 11:56 AM / 2 years ago

BRIEF-Madrigal Pharma completes Phase 2 enrollment for study on treatment of NASH

Aug 1 (Reuters) - Madrigal Pharmaceuticals Inc

* Completes enrollment in Phase 2 proof-of-concept study with MGL-3196 for treatment of NASH

* On track to release top-line results for primary endpoint, reduction of liver fat assessed by MRI-PDFF at 12 weeks by end of year​

* Will be on track to provide top-line 36 week results, which include final MRI-PDFF, end-of-study liver biopsy, in Q2 of 2018​

* Data from phase 2 study with MGL-3196 in heterozygous familial hypercholesterolemia to also become available by year end or very early in 2018​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below